OBJECTIVES: This study was conducted to determine whether urinary excretion of C-type natriuretic peptide (CNP) is elevated in acute decompensated heart failure (ADHF) and whether elevated levels predict adverse outcomes. BACKGROUND: Urinary CNP has been detected in patients with heart failure, but its clinical significance and prognostic utility, compared to established kidney injury biomarkers, in ADHF is unknown. METHODS: We measured 24-h urinary excretion and concurrent plasma concentrations of CNP22, CNP53, and NT-CNP53 in 58 ADHF patients and 20 healthy control subjects. Urinary kidney injury molecule (KIM)-1 and neutrophil gelatinase–associated lipocalin (NGAL) and plasma N-terminal pro-B type natriuretic peptide (NT-proBNP) were also measured. Mortality and all-cause rehospitalization/death were assessed over a follow-up of 1.5 ± 0.9 years. RESULTS: ADHF patients had higher urinary excretion of all 3 CNP molecular forms than did controls. Plasma CNP22 and CNP53 were elevated in ADHF but showed limited correlation with urinary excretion, suggesting that mainly renal-derived CNP appears in urine. Plasma NT-proBNP and urinary KIM-1 were also elevated in ADHF (p < 0.0001); urinary NGAL was similar to that in controls. At 6 months, event-free survival values in ADHF patients were 86% for mortality and 59% for all-cause rehospitalization/death. On Cox regression analysis, urinary NT-CNP53 was the only predictor of mortality (hazard ratio: 1.7; 95% confidence interval: 1.1 to 2.4; p = 0.01) and all-cause rehospitalization/death (hazard ratio: 1.8; 95% confidence interval: 1.3 to 2.4; p = 0.0004), even after adjustment. Integrated discrimination analysis suggested that urinary NT-CNP53 combined with plasma NT-proBNP improved the prediction of adverse outcomes. CONCLUSIONS: The findings from this study support the clinical utility of urinary CNP molecular forms. In ADHF, urinary NT-CNP53 correlated with prognosis, better predicted outcomes than did urinary NGAL and KIM-1, and improved the prognostic value of plasma NT-proBNP.
OBJECTIVES: This study was conducted to determine whether urinary excretion of C-type natriuretic peptide (CNP) is elevated in acute decompensated heart failure (ADHF) and whether elevated levels predict adverse outcomes. BACKGROUND: Urinary CNP has been detected in patients with heart failure, but its clinical significance and prognostic utility, compared to established kidney injury biomarkers, in ADHF is unknown. METHODS: We measured 24-h urinary excretion and concurrent plasma concentrations of CNP22, CNP53, and NT-CNP53 in 58 ADHFpatients and 20 healthy control subjects. Urinary kidney injury molecule (KIM)-1 and neutrophil gelatinase–associated lipocalin (NGAL) and plasma N-terminal pro-B type natriuretic peptide (NT-proBNP) were also measured. Mortality and all-cause rehospitalization/death were assessed over a follow-up of 1.5 ± 0.9 years. RESULTS:ADHFpatients had higher urinary excretion of all 3 CNP molecular forms than did controls. Plasma CNP22 and CNP53 were elevated in ADHF but showed limited correlation with urinary excretion, suggesting that mainly renal-derived CNP appears in urine. Plasma NT-proBNP and urinary KIM-1 were also elevated in ADHF (p < 0.0001); urinary NGAL was similar to that in controls. At 6 months, event-free survival values in ADHFpatients were 86% for mortality and 59% for all-cause rehospitalization/death. On Cox regression analysis, urinary NT-CNP53 was the only predictor of mortality (hazard ratio: 1.7; 95% confidence interval: 1.1 to 2.4; p = 0.01) and all-cause rehospitalization/death (hazard ratio: 1.8; 95% confidence interval: 1.3 to 2.4; p = 0.0004), even after adjustment. Integrated discrimination analysis suggested that urinary NT-CNP53 combined with plasma NT-proBNP improved the prediction of adverse outcomes. CONCLUSIONS: The findings from this study support the clinical utility of urinary CNP molecular forms. In ADHF, urinary NT-CNP53 correlated with prognosis, better predicted outcomes than did urinary NGAL and KIM-1, and improved the prognostic value of plasma NT-proBNP.
Authors: Sean P Collins; Kimberly W Hart; Christopher J Lindsell; Gregory J Fermann; Neal L Weintraub; Karen F Miller; Susan N Roll; Matthew I Sperling; Douglas B Sawyer; Alan B Storrow Journal: Eur J Heart Fail Date: 2012-06-25 Impact factor: 15.534
Authors: Alessandro Cataliotti; Mauro Giordano; Emanuela De Pascale; Gelsomina Giordano; Pietro Castellino; Michihisa Jougasaki; Lisa C Costello; Guido Boerrigter; Toshihiro Tsuruda; Paola Belluardo; Shang-Chiun Lee; Brenda Huntley; Sharon Sandberg; Lorenzo S Malatino; John C Burnett Journal: Am J Physiol Renal Physiol Date: 2002-09
Authors: Yang Chen; Gail J Harty; Ye Zheng; Seethalakshmi R Iyer; Shinobu Sugihara; S Jeson Sangaralingham; Tomoko Ichiki; Joseph P Grande; Hon-Chi Lee; Xiaoli Wang; John C Burnett Journal: Circ Res Date: 2019-05-10 Impact factor: 17.367
Authors: Tomoko Ichiki; John A Schirger; Brenda K Huntley; Frank V Brozovich; Joseph J Maleszewski; Sharon M Sandberg; S Jeson Sangaralingham; Soon J Park; John C Burnett Journal: J Mol Cell Cardiol Date: 2014-08-09 Impact factor: 5.000
Authors: Feby Savira; Ruth Magaye; Danny Liew; Christopher Reid; Darren J Kelly; Andrew R Kompa; S Jeson Sangaralingham; John C Burnett; David Kaye; Bing H Wang Journal: Br J Pharmacol Date: 2020-05-13 Impact factor: 8.739
Authors: Yang Chen; Ye Zheng; Seethalakshmi R Iyer; Gerald E Harders; Shuchong Pan; Horng H Chen; Tomoko Ichiki; John C Burnett; S Jeson Sangaralingham Journal: J Mol Cell Cardiol Date: 2019-04-04 Impact factor: 5.000
Authors: Xiao Ma; Yang Chen; Shawn H Reginauld; Christopher G Scott; Seethalakshmi R Iyer; Jacob J Schaefer; Tomoko Ichiki; Horng H Chen; Andrew D Rule; John C Burnett; S Jeson Sangaralingham Journal: JACC Heart Fail Date: 2021-07-07 Impact factor: 12.544